Dual biologic therapy in a patient with severe psoriasis and psoriatic arthritis, using guselkumab and bimekizumab: A case report and review of the literature
Open Access
- 14 January 2026
- journal article
- review article
- Published by SAGE Publications in Sage Open Medical Case Reports
- Vol. 14
Abstract
Dual biologic therapy is not often used in psoriasis and psoriatic arthritis due to cost and safety concerns, with limited literature supporting its use. We present a case of a 31-year-old man with severe plaque psoriasis and erosive psoriatic arthritis, refractory to multiple therapies. While guselkumab improved skin symptoms, joint inflammation persisted. Given the patient’s reluctance to discontinue guselkumab and his poor response to prior therapies, bimekizumab was added. This combination led to near-complete skin clearance and significant joint improvement within 3 months, with sustained benefits and no adverse effects at 17 months. This case illustrates how targeting multiple points in the interleukin-23/interleukin-17 pathway can improve outcomes in patients unresponsive to monotherapy. Dual biologic therapy may be a viable option for select patients with complex disease, though further research is needed to evaluate its long-term safety and efficacy.Keywords
This publication has 10 references indexed in Scilit:
- Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-AnalysisDermatology and Therapy, 2022
- Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritisJAAD Case Reports, 2019
- Successful Treatment of Refractory Plaque-Type Psoriasis and Psoriatic Arthritis With Guselkumab and Adalimumab Combination Therapy: A Case Report2019
- Psoriasis Pathogenesis and TreatmentInternational Journal of Molecular Sciences, 2019
- Role of the IL-23/IL-17 Axis in Psoriasis and Psoriatic Arthritis: The Clinical Importance of Its Divergence in Skin and JointsInternational Journal of Molecular Sciences, 2018
- Combination biologic therapy for the treatment of severe palmoplantar pustulosisJAAD Case Reports, 2017
- Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational studyBritish Journal of Dermatology, 2016
- Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case reportJAAD Case Reports, 2015
- Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.2013
- Combination Biologic Treatment of Refractory Psoriasis and Psoriatic ArthritisThe Journal of Rheumatology, 2012